Great Bay Bio would like to extend its sincere gratitude to all industry partners, experts, and participants for their enthusiastic support and active participation!
Recently, the 2nd Technical Seminar on Site-Specific Integration for Cell Line Development, jointly organized by Great Bay Bio and BSI Media, was successfully held. Industry experts, representatives from biopharmaceutical companies, and technical professionals gathered to exchange insights and explore the latest advances in site-specific integration technologies, creating an engaging and highly interactive atmosphere.
Technical Presentations | Exploring Key Advances in Site-Specific Integration for Cell Line Development
The seminar focused on several cutting-edge topics, including complex antibody development, AI-assisted cell line development, next-generation site-specific integration platforms, and synthetic promoters. Through scientific insights and practical case studies, the speakers explored the application potential of site-specific integration technologies in biopharmaceutical development.
Lung-JR Lin, Chief Scientist of Great Bay Bio, delivered a presentation titled "Enabling Complex Antibody Development Through Site-Specific Integration: Breaking Through Key Challenges in Bispecific and Multispecific Antibody-Producing Cell Line Development."
He discussed the key challenges associated with developing production cell lines for complex antibodies, highlighting the value of site-specific integration in coordinating multi-chain expression, optimizing cell line development strategies, and improving the development of production cell lines for complex antibodies. His presentation offered new technical perspectives for the efficient development of bispecific and multispecific antibodies.
Chuanlong Tang, Director of Cell Line Development at Shanghai Jiyu Pharmaceutical Technology Co., Ltd., presented "Integrating Site-Specific Integration and AI Prediction to Empower End-to-End Cell Line Development from PCC to IND."
Focusing on cell line development requirements from Preclinical Candidate (PCC) selection to Investigational New Drug (IND) submission, he explored the complementary application of site-specific integration and AI prediction. He also discussed how data-driven decision-making, development workflow optimization, and early identification of critical risks can improve development efficiency and predictability.
Xiaoyu Bai, Deputy Director of Cell Line Development at WuXi Biologics, presented "WuXiaTruesite: A Next-Generation High-Performance Cell Line Development Platform for More Efficient Biopharmaceutical Development."
She introduced the technological concepts and application potential of a next-generation site-specific integration platform, highlighting cell line development efficiency, expression performance, workflow optimization, and platform-based applications. Her presentation explored how technological innovation can provide efficient and reliable support for biopharmaceutical development.
Songtao Zhou, Cell Line Development Manager at Shanghai Hongcheng Pharmaceutical Co., Ltd., delivered a presentation titled "An Overview of Site-Specific Integration Platforms and the Development and Application of Synthetic Promoters."
He introduced the underlying principles and applications of site-specific integration platforms, together with strategies for the design, development, and application of synthetic promoters. His presentation explored the coordinated optimization of gene integration strategies and expression regulatory elements, providing valuable technical insights into improving cell line expression performance and supporting the development of diverse biopharmaceutical products.
Panel Discussion | Addressing Stability Challenges in Scaling Up Site-Specific Integration Cell Lines from Early Development to GMP Clinical Manufacturing
To further facilitate in-depth technical discussions, the seminar featured a panel discussion titled "Stability Challenges and Solutions in Scaling Up Site-Specific Integration Cell Lines from Early Development to GMP Clinical Manufacturing."
The discussion brought together Kane Qi, Chief Business Officer of Great Bay Bio; Longzhi Lin, Chief Scientist of Great Bay Bio; Chuanlong Tang, Director of Cell Line Development at Shanghai Jiyu Pharmaceutical Technology Co., Ltd.; Xiaoyu Bai, Deputy Director of Cell Line Development at WuXi Biologics; and Songtao Zhou, Cell Line Development Manager at Shanghai Hongcheng Pharmaceutical Co., Ltd.
The panelists shared their perspectives on several critical topics, including genetic and expression stability, the transition from laboratory-scale development to manufacturing scale, risk identification during technology transfer, and quality and control requirements for GMP clinical sample production.
They explored ways to strengthen collaboration across cell line development, process development, and manufacturing, offering valuable perspectives on advancing site-specific integration technologies from research applications toward industrial implementation.
The event attracted strong participation and generated lively discussions, reflecting the industry's growing interest in site-specific integration technologies for cell line development and their application potential.
As a joint organizer, Great Bay Bio demonstrated its strong technical expertise and commitment to advancing the field of site-specific integration for cell line development. The seminar provided a valuable platform for high-quality industry exchange, bringing together cutting-edge technologies, practical experience, and industrial needs while fostering collaboration and shared perspectives across the industry.
Looking ahead, Great Bay Bio will continue to drive technological innovation and platform advancement, deepen the integration of AI with biopharmaceutical R&D, and work closely with industry partners to accelerate innovation and expand the application of site-specific integration technologies, ultimately supporting more efficient biopharmaceutical development and industrialization.
